News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Han All Pharmaceutical Co., Ltd. (009420.KS) Acquires Global Rights To Nautilus Biotech's Protein Engineering Technology For Developing Novel Oral And Injectable Therapeutic Proteins



6/29/2009 1:49:11 PM

SEOUL, KOREA, June 24, 2009: HanAll Pharmaceutical Co., Ltd. announced that the company has been awarded global and exclusive ownership to all patents, data and documentation related to Nautilus Biotech’s high-speed throughput protein engineering technology and products. With only a small number of companies working in this area, this positions HanAll as a leader in the development of proprietary and novel protein therapeutics.


Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES